Harmine and exendin
Three months of combination treatment restored glucose homeostasis in a streptozotocin-induced model of diabetes, with effects lasting for at least a month after treatment withdrawal. Initial analysis suggested that these effects occurred through altered β cell proliferation, function, and survival.
The augmentation in human β cell mass occurred through mechanisms that included enhanced human β cell proliferation, function, and survival.
Harmine and exendin
Here, using an optimized immunolabeling- enabled three- dimensional imaging of solvent- cleared organs (iDISCO+) protocol in mouse kidneys bearing human islet grafts, we demonstrate that combination of a DYRK1A inhibitor with exendin - 4 increases actual human β cell mass in vivo by a mean of four- to sevenfold in diabetic and nondiabetic mice ...
Here, using an optimized immunolabeling-enabled three-dimensional imaging of solvent-cleared organs (iDISCO +) protocol in mouse kidneys bearing human islet grafts, we demonstrate that combination of a DYRK1A inhibitor with exendin-4 increases actual human β cell mass in vivo by a mean of four- to sevenfold in diabetic and nondiabetic mice ...
PDF Harmine and exendin
Cotreatment with low doses of harmine and exendin-4 led to a substantial increase in human β cell proliferation and mass expan- sion without α cell proliferation at 1 or 4 weeks of treatment and ...
Rosselot, C. et al. Harmine and exendin-4 combination therapy safely expands human β cell mass in vivo in a mouse xenograft system. Sci. Transl Med. 16, eadg3456 (2024) Article PubMed Google ...
Combination treatment can increase human insulin
Harmine and exendin-4 combination therapy safely expands human β cell mass in vivo in a mouse xenograft system. Science Translational Medicine, 2024; 16 (755) DOI: 10.1126/scitranslmed.adg3456
Harmine plus exendin-4 safely expands transplanted human beta cells in mice, demonstrating for the first time a drug combination that increases insulin-producing cell mass.
Key Details About Harmine And Exendin 4 Combination Therapy Safely Expands Human Β Cell
Our studies provide unequivocal documentation that treatment with the harmine and exendin-4 combination can lead to actual increases in human β- cell mass in diabetic conditions suggesting that β- cell replenishment might be possible in humans with diabetes.
GLP1R agonists such as Exendin-4 (E) together with DYRK1A inhibitors such as Harmine (H) significantly increase human β- cell replication in vitro and in vivo. Importantly, 3-month treatment with H+E combination markedly increases human beta cell mass (∼7-fold) in islets transplanted in immunosuppressed mice, beyond the increase induced by ...